Downregulation of Kv7.4 channel activity in primary and secondary hypertension

Circulation

Volumn 124, Issue 5, 2011, Pages 602-611

  Jepps, Thomas A ^a   Chadha, Preet S ^a   Davis, Alison J ^a   Harhun, Maksym I ^a   Cockerill, Gillian W ^a   Olesen, Soøren P ^b,c   Hansen, Rie S ^b,c   Greenwood, Iain A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b NEUROSEARCH A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gene expression; Hypertension; KCNQ potassium channels; Vasodilation

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; FLINDOKALNER; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LINOPIRDINE; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; POTASSIUM CHANNEL KV7.2; POTASSIUM ION; RETIGABINE; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; HYPERTENSION; ISOLATED HEART; MALE; MESENTERIC ARTERY; MOUSE; MUSCLE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; POTASSIUM CURRENT; POTENCY DISORDER; PRIMARY HYPERTENSION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION;

ANGIOTENSIN II; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; CARBAMATES; DOWN-REGULATION; HYPERTENSION; INDOLES; KCNQ POTASSIUM CHANNELS; MALE; MEMBRANE POTENTIALS; MESENTERIC ARTERIES; MICE; PHENYLENEDIAMINES; RATS; RATS, INBRED SHR; RATS, WISTAR; VASOCONSTRICTOR AGENTS;

EID: 80051546419     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.032136     Document Type: Article

References (47)

1. Lund-Johansen P. Haemodynamics in essential hypertension. Clin Sci (Lond). 1980;59:343s-354s. (Pubitemid 11219723)
2. Gebremedhin D, Fenoy FJ, Harder DR, Roman RJ. Enhanced vascular tone in the renal vasculature of spontaneously hypertensive rats. Hypertension. 1990;16:648-654.
3. 2+ entry, and gene expression in cerebral arteries of hypertensive rats. Am J Physiol Heart Circ Physiol. 2001;281:H2559-H2567.
4. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, McKinnon D. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998;282:1890-1893. (Pubitemid 28555268)
5. + channel subunit, Erg1 and KCNQ2/3, contribute to the M-like current in a mammalian neuronal cell. J Neurosci. 1999;19:7742-7756. (Pubitemid 30225774)
6. Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000;275:24089-24095. (Pubitemid 30624700)
7. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci. 2000;1:21-30.
8. Ks potassium channel. Nature. 1996;384:80-83. (Pubitemid 26374592)
9. + channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci U S A. 2000;97:4333-4338. (Pubitemid 30226133)
10. + channel KvLQT1 and epithelial function. Pflugers Arch. 2000;440:202-206. (Pubitemid 30414646)
11. Mackie AR, Byron KL. Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention. Mol Pharmacol. 2008;74:1171-1179.
12. Greenwood IA, Ohya S. New tricks for old dogs: KCNQ expression and role in smooth muscle. Br J Pharmacol. 2009;156:1196-1203.
13. + channel KCNQ genes in human arteries. Br J Pharmacol. 2011;162:42-53.
14. Ohya S, Sergeant GP, Greenwood IA, Horowitz B. Molecular variants of KCNQ channels expressed in murine portal vein myocytes: a role in delayed rectifier current. Circ Res. 2003;92:1016-1023. (Pubitemid 36588501)
15. Yeung SY, Pucovský V, Moffatt JD, Saldanha L, Schwake M, Ohya S, Greenwood IA. Molecular expression and pharmacological identification of a role for Kv7 channels in murine vascular reactivity. Br J Pharmacol. 2007;151:758-770. (Pubitemid 47075320)
16. Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, Byron KL. Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther. 2008;325:475-483. (Pubitemid 351574788)
17. Joshi S, Sedivy V, Hodyc D, Herget J, Gurney AM. KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J Pharmacol Exp Ther. 2009;329: 368-376.
18. Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, Greenwood IA. Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol. 2010;588: 3277-3293.
19. Yeung SY, Lange W, Schwake M, Greenwood IA. Expression profile and characterisation of a truncated KCNQ5 splice variant. Biochem Biophys Res Commun. 2008;371:741-746.
20. + currents. BrJ Pharmacol. 2008;155:62-72.
21. Yeung SY, Greenwood IA. Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. Br J Pharmacol. 2005;146:585-595. (Pubitemid 41487075)
22. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol. 2000;58:253-262. (Pubitemid 30497468)
23. + channel sensitivity to the anticonvulsant retigabine. J Neurosci. 2005;25:5051-5060. (Pubitemid 40712849)
24. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol. 2005;67:1009-1017. (Pubitemid 40410403)
25. Bentzen BH, Schmitt N, Calloe K, Dalby Brown W, Grunnet M, Olesen SP. The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006;51:1068-1077. (Pubitemid 44691813)
26. Schleifenbaum J, Köhn C, Voblova N, Dubrovska G, Zavarirskaya O, Gloe T, Crean CS, Luft FC, Huang Y, Schubert R, Gollasch M. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. J Hypertens. 2010;28:1875-1882.
27. + channels in the function of rat aortic smooth muscle cells. Br J Pharmacol. 2004;143:303-317. (Pubitemid 39315151)
28. Davis AJ, Forrest AS, Jepps TA, Valencik ML, Wiwchar M, Singer CA, Sones WR, Greenwood IA, Leblanc N. Expression profile and protein translation of TMEM16A in murine smooth muscle. Am J Physiol Cell Physiol. 2010;299:C948-C959.
29. Shah MM, Mistry M, Marsh SJ, Brown DA, Delmas P. Molecular correlates of the M-current in cultured rat hippocampal neurons. J Physiol. 2002;544:29-37. (Pubitemid 35153811)
30. -δ δCt method. Methods. 2001;25: 402-408. (Pubitemid 34164012)
31. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Stroøbaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther. 2005;314: 282-922.
32. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA. Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol. 1998;274:E867-E876.
33. Jones A, Deb R, Torsney E, Howe F, Dunkley M, Gnaneswaran Y, Gaze D, Nasr H, Loftus IM, Thompson MM, Cockerill GW. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation. 2009;119:3125-3132.
34. Daugherty A, Rateri DL, Charo IF, Owens AP, Howatt DA, Cassis LA. Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond). 2010;118:681-689.
35. Morecroft I, Murray A, Nilsen M, Gurney AM, MacLean MR. Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009;157:1241-1249.
36. Cox RH, Folander K, Swanson R. Differential expression of voltage-gated K(+) channel genes in arteries from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 2001;37:1315-1322. (Pubitemid 34163588)
37. + channel expression in arteries of Wistar-Kyoto and spontaneously hypertensive rats. Am J Hypertens. 2008;21:213-218. (Pubitemid 351231575)
38. Tobin AA, Joseph BK, Al-Kindi HN, Albarwani S, Madden JA, Nemetz LT, Rusch NJ, Rhee SW. Loss of cerebrovascular Shaker-type K(+) channels: a shared vasodilator defect of genetic and renal hypertensive rats. Am J Physiol Heart Circ Physiol. 2009;297:H293-H303.
39. Brenner R, Peréz GJ, Bonev AD, Eckman DM, Kosek JC, Wiler SW, Patterson AJ, Nelson MT, Aldrich RW. Vasoregulation by the beta1 subunit of the calcium-activated potassium channel. Nature. 2000;407:870-876.
40. 2+] and diameter in mouse cerebral arteries. J Appl Physiol. 2001;91:1350-1354. (Pubitemid 32803932)
41. + channels in vascular smooth muscle during hypertension. J Clin Invest. 2003;112:717-724. (Pubitemid 38057712)
42. Amberg GC, Santana LF. Downregulation of the BK channel beta1 subunit in genetic hypertension. Circ Res. 2003;93:965-971. (Pubitemid 37433234)
43. + channel in murine gastrointestinal smooth muscles. Am J Physiol Gastrointest Liver Physiol. 2009; 297:G107-G115.
44. McCallum LA, Greenwood IA, Tribe RM. Expression and function of Kv7 channels in murine myometrium throughout oestrous cycle. Pflugers Arch. 2009;457:1111-1120.
45. Rode F, Svaloø J, Sheykhzade M, Roønn LC. Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder. Eur J Pharmacol. 2010;638:121-127.
46. Dick GM, Tune JD. Role of potassium channels in coronary vasodilation. Exp Biol Med (Maywood). 2010;235:10-22.
47. Numaguchi K, Egashira K, Sakata M, Shimokawa H, Takeshita A. Coronary vascular ATP-sensitive potassium channels are activated to a greater extent in spontaneously hypertensive rats than in Wistar-Kyoto rats. J Hypertens. 1996;14:183-189. (Pubitemid 26121860)